Nurix Therapeutics Hosts Webcast to Discuss Trial Data
SAN FRANCISCO — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical organization dedicated to pioneering targeted protein degradation therapies, has exciting news to share. The company will be hosting a live webcast conference call to unveil significant findings from its ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). This event is scheduled for 8:00 a.m. ET, on June 12, 2025, following the presentation of findings at a major hematology congress.
Webcast and Conference Call Details
Participants can expect a comprehensive discussion of the latest clinical trial data during this conference call. The access details for the live event are as follows:
Date and Time: Thursday, June 12, at 8:00 a.m. ET / 2:00 p.m. CEST
Access Instructions: Interested individuals can join the live webcast through the company's official investors' section on their website. For those wishing to participate via telephone, U.S. participants can dial 877-346-6112 and international participants can reach the call at 1-848-280-6350. A recording of the call and webcast will be available on Nurix's website for approximately 30 days for those who are unable to attend live.
Presentations at EHA2025
Nurix has valuable contributions to share at the European Hematology Association Congress, specifically regarding bexobrutideg (NX-5948). Here’s a summary of the key presentations:
- Title: Bexobrutideg (NX-5948), a novel BTK degrader, shows promising clinical efficacy in relapsed refractory CLL
- Presenting Author: Talha Munir M.B. Ch.B., Ph.D.
- Session Title: Poster Session 1
- Session Date: Friday, June 13 (18:30 - 19:30 CEST)
- Abstract ID: PF571
- Title: Bexobrutideg (NX-5948) demonstrates high clinical efficacy in Waldenström macroglobulinemia
- Presenting Author: Dima El-Sharkawi, M.B., B.S., Ph.D.
- Session Title: Poster Session 2
- Session Date: Saturday, June 14 (18:30 - 19:30 CEST)
- Abstract ID: PS1883
About Bexobrutideg (NX-5948)
Bexobrutideg is an innovative small molecule designed to degrade BTK and is currently under assessment in a Phase 1 clinical trial for patients suffering from relapsed or refractory B cell malignancies. This investigational treatment is notable for its oral bioavailability and ability to penetrate the brain, making it a promising candidate in oncology.
Learn More About Nurix Therapeutics
Nurix Therapeutics is at the forefront of drug design, focusing on developing medications that target protein degradation. Their approach is aimed primarily at enhancing therapies for patients battling cancer and inflammatory diseases. The company is advancing its pipeline that includes additional promising therapies such as BTK degraders and CBL-B inhibitors, underscoring their commitment to translating science and AI-driven discoveries into effective clinical solutions.
Frequently Asked Questions
What is nurix therapeutics focusing on?
Nurix Therapeutics is focused on discovering, developing, and commercializing targeted protein degradation medicines to enhance treatment options for various diseases.
When is the webcast scheduled?
The webcast conference call is scheduled for June 12, 2025, at 8:00 a.m. ET.
How can I access the webcast?
The webcast can be accessed on Nurix's official investor page on their website.
What are the objectives of the clinical trial for bexobrutideg?
The clinical trial aims to evaluate the safety and efficacy of bexobrutideg in treating patients with relapsed or refractory B cell malignancies.
Who can participate in the conference call?
Anyone interested may participate via the provided dial-in numbers or join through the webcast link available on the official website.